Vivoryon Therapeutics to Present a Clinical Update on its Novel Oral Small Molecule Varoglutamstat at Clinical Trials on Alzheimer’s Disease Conference (CTAD)

Vivoryon Therapeutics Announces Successful Listing of 2,054,796 Shares
Vivoryon Therapeutics N.V. to Present at the 2023 BIO CEO & Investor Conference